Investors focused on the Medical space have likely heard of Cumberland Pharmaceuticals (CPIX - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? Let's take a closer look at the stock's year-to-date performance to find out.
Cumberland Pharmaceuticals is a member of our Medical group, which includes 844 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. CPIX is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past three months, the Zacks Consensus Estimate for CPIX's full-year earnings has moved 216.67% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Our latest available data shows that CPIX has returned about 5.47% since the start of the calendar year. At the same time, Medical stocks have gained an average of 1.42%. As we can see, Cumberland Pharmaceuticals is performing better than its sector in the calendar year.
Looking more specifically, CPIX belongs to the Medical - Drugs industry, a group that includes 174 individual stocks and currently sits at #77 in the Zacks Industry Rank. This group has gained an average of 2.73% so far this year, so CPIX is performing better in this area.
Going forward, investors interested in Medical stocks should continue to pay close attention to CPIX as it looks to continue its solid performance.